Suicidal thoughts can be aroused due to various underlying factors such as financial burden, social issues or drug side effects. Treatment for suicidal thoughts includes psychotherapy, medications, addiction treatment, and family support. Anti-depressants and anti-psychotics are the most widely used medications for treating suicidal tendencies. According to the World Health Organization (WHO), over 800,000 people die due to suicide annually. Development of an effective anti-suicidal drug could be a major breakthrough in reducing the death toll. Currently, non-profit organizations such as Stop Suicide, Stop Youth Suicide, and American Foundation for Suicide Prevention are providing moral and social support to people with reported suicidal thoughts. This however, is ineffective until the organization is alerted of the person at risk for suicide.
Market Dynamics
Off-label use of these drugs for suicidal ideation has been a practice for years, as there are no approved anti-suicide specific drug yet. However, the dynamics is expected to change in the following few years with the launch of first oral therapeutic drug for acute suicidal ideation. This would disrupt the use of antidepressants and anti-psychotic drugs for the treatment of suicidal tendencies. Suicidal incidences are high in low and middle income countries according to the WHO 2016 statistics. Although the incidence in Asia, East Africa, and Eastern European region is high, these regions lag in terms of availability of affordable medications and healthcare facilities. Therefore developed economies of North America and Western Europe are key target regions for manufacturers in the near future. Rampant economic growth and projected strengthening of the healthcare infrastructure in emerging economies in towards the first half of the following decade is projected to shift the focus of these companies towards highly populous regions of India and China in the long run.
Key features of the study:
- This report provides in-depth analysis of the anti-suicide drugs and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global anti-suicide drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
- Key companies covered as a part of this study include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson
- Insights from this report would allow marketers and the management of companies to make informed decision with respect to their future product launch, competitive scenario, geographic expansion, and marketing tactics
- The global anti-suicide devices market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts
- Various strategy matrices used in analyzing the anti-suicide drugs market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
- Global Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressants and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Global Anti-Suicide Drugs Market, By Geography:
- North America
- U.S.
- U.S. Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Canada
- Canada Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Europe
- U.K.
- U.K Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Germany
- Germany Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Italy
- Italy Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- France
- France Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Spain
- Spain Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Russia
- Russia Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Rest of Europe
- Rest of Europe Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Asia-Pacific
- China
- China Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- India
- India Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Japan
- Japan Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- ASEAN
- ASEAN Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Australia
- Australia Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- South Korea
- South Korea Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Rest of Asia Pacific (APAC)
- Rest of Asia Pacific (APAC) Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Latin America
- Brazil
- Brazil Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Mexico
- Mexico Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Argentina
- Argentina Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Rest of Latin America
- Rest of Latin America Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Middle East
- GCC
- GCC Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Israel
- Israel Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Rest of Middle East
- Rest of Middle East Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Africa
- North Africa
- North Africa Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Central Africa
- Central Africa Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- South Africa
- South Africa Anti-Suicide Drugs Market, By Drug Class:
- Anti-Depressant and Anti-Anxiety Drugs
- Anti-Psychotic Drugs
- NMDA Antagonist
- Antibiotic Analog
- Company Profiles
- Pfizer, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Future Plans
- AstraZeneca plc
- Eli Lilly and Company
- Allergan plc
- GlaxoSmithKline plc
- Merck & Co., Inc.
- H. Lundbeck A/S
- NeuroRx, Inc.
- Johnson & Johnson
“*” marked represents similar segmentation in other categories in the respective section.
